



Instructions for Use



For use under an Emergency Use Authorization (EUA) Only

For *In Vitro* Diagnostic Use Only



Clear Dx™ SARS-CoV-2 Test

For use with Clear Dx™ System Only

Table of Contents

Contents

| | |
|---|-------------------------------------|
| General Information | 4 |
| Intended Use | 4 |
| Summary and Explanation of Test..... | 4 |
| Principles of the Procedure | 5 |
| Warnings and Precautions..... | 6 |
| Equipment and Materials | 8 |
| Storage and Handling Requirements for Reagent Kits Provided..... | Error! Bookmark not defined. |
| Additional Materials Required and Provided | 8 |
| Special Instrumentation Required (but not Provided) | Error! Bookmark not defined. |
| Additional Materials and Reagents Required (but not Provided) | 12 |
| Procedures | 133 |
| Clear Dx™ System Setup and Initialization | 13 |
| Specimen Collection, Transport and Storage | 13 |
| Sample Registration in the Clear View Application | 13 |
| Company, Client, and User Creation and Management..... | 15 |
| Sample Preparation | 24 |
| Instrument Maintenance Check | 24 |
| Instrument Setup and Loading | 24 |
| Preparation..... | 26 |
| Load Samples and Controls | 26 |
| Load Flow Cell..... | 26 |
| Load Plates..... | 27 |
| Load Tips..... | 27 |
| Load Reagent Tubes | 27 |
| Complete Flow Cell QC Check..... | 27 |
| Pre-Run Check | 27 |
| Secure Index Plate(s)..... | 28 |
| Start Test Run | 28 |

| | |
|---|-----------|
| Data Analysis | 28 |
| Results Access..... | 28 |
| Reporting Clear Dx™ Results | 30 |
| Post Processing Procedures..... | 31 |
| Emptying the Clear Dx™ System..... | 31 |
| Technical Support | 33 |
| Quality Control..... | 33 |
| Interpretation of Results | 34 |
| Limitations of the test..... | 36 |
| Conditions of Authorization for Labs | 37 |
| Clear Dx™ SARS-CoV-2 Test Performance | 38 |
| Limit of Detection (LoD) - Analytical Sensitivity | 38 |
| Inclusivity | 39 |
| Cross-reactivity (Exclusivity) | 40 |
| Clinical Performance Evaluation..... | 44 |
| Symbols Legend | 45 |

General Information

Intended Use

Clear Dx™ SARS-CoV-2 Test is a multiplexed RT-PCR and next-generation DNA sequencing (NGS) *in vitro* diagnostic test on the Oxford Nanopore GridION Sequencer intended for the qualitative detection of SARS-CoV-2 viral RNA in human nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate swab, nasopharyngeal wash/aspirate, nasal aspirate, and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The Clear Dx™ SARS-CoV-2 Test is intended for use by qualified clinical laboratory personnel specifically instructed and trained on the Clear Dx™ system, in the techniques of real-time PCR and NGS, and *in vitro* diagnostic procedures. The Clear Dx™ SARS-CoV-2 Test is only for use under the Food and Drug Administration's Emergency Use Authorization.

Summary and Explanation of Test

Coronavirus disease 2019 (COVID-19) is a severe respiratory disease that was initially identified in Wuhan, China but has become a global pandemic since then. The virus that causes COVID-19 is designated as Severe Respiratory Syndrome Coronavirus 2 (SARS CoV-2); previously, it was referred to as 2019 Novel Coronavirus (2019 nCoV). SARS-CoV-2 belongs to the same family of betacoronaviruses as that of SARS CoV and MERS CoV that have caused epidemics in humans in 2003 and 2012 respectively. All these betacoronaviruses are enveloped, positive-sense, single-stranded RNA viruses with relatively large genome sizes that bind to specific receptors on the host cell and cause respiratory illnesses.

The Clear Dx™ SARS-CoV-2 Test is a targeted next-generation sequencing test intended for detection of SARS-CoV-2 virus RNA under FDA Emergency Use Authorization. This test is fully automated to run

on the Clear Dx™ system and can process up to 192 samples in a run including positive and negative run controls. The automated test goes from extracted RNA from clinical respiratory specimens to a full report with no human intervention.

Principles of the Procedure

The entire workflow for the detection of SARS-CoV-2 RNA includes multiple steps - specimen collection from patients, extraction of RNA from the clinical specimens and subsequently testing for the presence of SARS CoV-2. Clear Dx™ SARS-CoV-2 Test, which includes the targeted NGS-based assay using the extracted RNA, liquid handling steps, bioinformatic analysis and reporting, is fully automated on the Clear Dx™ system.

The Clear Dx™ system (illustrated in Figure 1) uses a Hamilton STAR robotic platform for automation of liquid handling and includes all the required ancillary equipment, such as thermocyclers, barcode reader, and magnet block, needed for the test. The system also houses the GridION nanopore sequencer developed by Oxford Nanopore Technologies (ONT).



Figure 1. Clear Dx™, a fully automated platform from RNA to results

An overview of the different steps involved in the test is illustrated in the figure below.



Automated workflow of the Clear Dx™ SARS-CoV-2 Test

RNA Extraction:

The Clear Dx™ SARS-CoV-2 Test starts with RNA (in elution buffer), manually extracted from respiratory specimens, using MagMAX Viral RNA Isolation Kit (catalog # AM1939) through the manual workflow as recommended by the manufacturer. It is not provided with the test kit.

Assay & Bioinformatics workflow:

The automated Clear Dx™ SARS-CoV-2 Test starts with synthesizing cDNA from the extracted RNA for each of the samples loaded into the well plates in independent reverse transcription reactions. Then the viral target amplicons are captured from the synthesized cDNA through a multiplex PCR process using a panel of barcoded target capture primers. After this “Target-capture” PCR step, there is a Solid Phase Reversible Immobilization (SPRI) bead-based cleanup during which all the excess primers and any short amplification products are removed. Following this, the amplicons are subjected to another round of PCR, termed as “Barcoding PCR”, where the second set of barcodes are added to the amplicons using the rapid library primers from ONT. Following this step, the dual barcoded amplicons from all the samples are pooled together and cleaned up through another SPRI bead process. After this step, the ONT sequencing adapters are ligated to all the barcoded amplicons and then sequenced on the GridION sequencer.

Our bioinformatics pipeline, Clear Dx™ BIP (version Dv5.0) performs a series of steps including demultiplexing, error correction and alignments on the sequencing reads of the amplicons to make the detection calls. The SARS-CoV-2 detection algorithm takes the relative ratios of the sequencing signal for SARS-CoV-2 primers, the internal PCR control, and the human housekeeping gene into account to make an invalid/positive/negative call. Samples with insufficient total read coverage are classified as invalid. The remaining samples have their SARS-CoV-2 signal compared to empirically derived thresholds. These thresholds distinguish true SARS-CoV-2 signal from noise. Each primer has its own threshold and the pipeline leverages the redundancy of SARS-CoV-2 specific primers to make a call.

Warnings and Precautions

- ✓ For *in vitro* diagnostic use only
- ✓ For prescription use only
- ✓ For Emergency Use Authorization (EUA) only

- ✓ The Clear Dx™ SARS-CoV-2 Test has not been FDA cleared or approved
- ✓ The Clear Dx™ SARS-CoV-2 Test has been authorized by FDA under an Emergency Use Authorization (EUA) for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high complexity tests.
- ✓ The Clear Dx™ SARS-CoV-2 Test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- ✓ The Clear Dx™ SARS-CoV-2 Test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- ✓ Carefully read the entire Instructions for Use for the Clear Dx™ system.
- ✓ Only personnel adequately trained on the use of this assay and in handling potentially infectious materials should perform these procedures.
- ✓ The Clear Dx™ system method includes sample preparation procedures that handle concentrated viral RNA. Because viruses can cause human illness, appropriate safety precautions must be taken when handling samples, media, reagents, and other supplies and equipment that could be contaminated with potentially pathogenic virus/bacteria.
- ✓ Reagents used with the system should pose no hazards when used as directed. Before using the reagents, please review the Safety Data Sheets (SDS) included with your Clear Dx™ purchase.
- ✓ Use only supplied or specified disposable laboratory ware.
- ✓ Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of being infected with SARS-CoV-2 as outlined in CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019 Novel Coronavirus (2019-nCoV).
- ✓ Do not attempt to place or adjust or remove something from inside the robot once it has started. An accidental collision with the robotic liquid handling arm can result in erroneous results.
- ✓ Wear disposable, powderless gloves, protective eye wear, and laboratory coats when handling specimens and reagents. Wash hands thoroughly after handling specimens and reagents.
- ✓ Dispose of all material that have come into contact with specimens and reagents in accordance with applicable national, international, and regional regulations.
- ✓ Maintain proper storage conditions during specimen shipping to ensure the integrity of the specimen. Specimen stability under shipping conditions other than those recommended has not been evaluated.

- ✓ Avoid cross-contamination during the specimen handling steps. Specimens can contain extremely high levels of virus or other organisms. Ensure that specimen containers do not come in contact with one another, and discard used materials without passing them over any open containers. Change gloves if they come in contact with specimens.
- ✓ Do not use the reagents and controls after the expiration date.
- ✓ Store assay components at the recommended storage condition. See Equipment and Materials for reagent storage and handling requirements (page 8-10), and Clear Dx™ Test Procedure (page 12-32) for more information. Do not freeze Clear DX Reagent Kit 3 (CLDX-K300). Doing so will adversely impact assay performance.
- ✓ Detection of SARS-CoV-2 RNA on the Clear Dx™ SARS-CoV-2 Test may be affected by sample collection methods, patient factors (ex. Presence of symptoms) and/or stage of infection.
- ✓ Quality control requirements must be performed in conformance with local, state, and/or federal regulations or accreditation requirements and your laboratory's standard quality control procedures.

Equipment and Materials

Storage and Handling Requirements for Reagent Kits Provided

Pre-packaged reagents & kits for Clear Dx™ SARS-CoV-2 Test:

Clear Dx™ SARS-CoV-2 Test comes with 5 reagent kits, labeled CLDX-Kxxx, as shown in the table below. These kits contain different pre-packaged and metered reagents such as primers, enzyme mixes, buffers, SPRI beads and sequencing-specific reagents from ONT.

| SKU # | Kit Name | Description | # of tubes OR 96-well plates | Storage conditions | Max. # of samples / Kit |
|-----------|----------------------------------|-----------------------------|------------------------------|--------------------|-------------------------|
| CLDX-K100 | Clear Dx™ Reagent Kit 1 | Library Prep Reagents | 22 | -20 °C | 192 |
| CLDX-K200 | Clear Dx™ Reagent Kit 2 | Enzyme mixes for RT and PCR | 8 | -20 °C | 192 |
| CLDX-K300 | Clear Dx™ Reagent Kit 3 | SPRI beads | 4 | 2-8 °C | 192 |
| CLDX-K400 | Clear Dx™ SARS-CoV-2 Index 1 Kit | Barcoded primers set 1 | 1 | -20 °C | 96 |
| CLDX-K500 | Clear Dx™ SARS-CoV-2 Index 2 Kit | Barcoded primers set 2 | 1 | -20 °C | 96 |

Reagent & kit configuration for Clear Dx™ SARS-CoV-2 test

All the reagents will be sealed with pierceable foil to avoid evaporation and contamination. During the automated run, the foil seal will be pierced by the pipette tips. All the critical reagents and the primer plates (CLDX-K400 & CLDX-K500) will be barcoded with 2D barcodes to track the reagent usage for the run and also to track against their expiration dates. All the kit boxes and reagents will be clearly labeled. The reagent tubes will have colored lids to avoid operator error. The details of the components of the kits are listed in the table below.

| Item # | Item Description | Components | Vol, ul | Conc | Qty | UOM |
|-------------------|--|--|---------|--------------|----------|------------|
| CLDX-K100 | Clear DX Reagent Kit 1 | | | | 1 | Kit |
| CLDX-K100-101 | LP1: EDTA/Waste Tube | EDTA | 1,400 | 200 mM | 1 | Tube |
| CLDX-K100-102 | LP2: Pool Tube | Empty Tube | N/A | N/A | 1 | Tube |
| CLDX-K100-103 | LP3: Internal Control Tube | G-block internal control DNA | 1,500 | 0.015 fg/uL | 1 | Tube |
| CLDX-K100-104 | LP4: Water Tube | Molecular Grade Water | 1,800 | N/A | 1 | Tube |
| CLDX-K100-105 | LP5: Water Tube | Molecular Grade Water | 1,800 | N/A | 1 | Tube |
| CLDX-K100-106 | LP6: Sequence Library Control Tube | Tris-HCl buffer with g-block control primers | 15 | 10 mM | 1 | Tube |
| CLDX-K100-107 | LP7: CL Elution Buffer Tube | Tris-HCl buffer | 50 | 10 mM | 1 | Tube |
| CLDX-K100-108 | LP8: Rapid Adapter (RAP 8x) Tube | ONT Rapid Adaptor | 8 | Proprietary | 1 | Tube |
| CLDX-K100-109 | LP9: Library Loading Beads (LLB) Tube | ONT Library Loading Beads | 45 | Proprietary | 1 | Tube |
| CLDX-K100-110 | LP10: Sequencing Buffer (SQB) Tube | ONT Sequencing Buffer | 50 | Proprietary | 1 | Tube |
| CLDX-K100-111 | LP11: Flush Tether (FLT) Tube | ONT Flush Tether | 50 | Proprietary | 1 | Tube |
| CLDX-K100-112 | LP12: Flush Buffer (FLB) Tube | ONT Flush Buffer | 1,170 | Proprietary | 1 | Tube |
| CLDX-K100-113 | LP13: Ethanol Tube | Clear Labs, Inc. | Empty | N/A | 1 | Tube |
| CLDX-K100-114 | LP14: Ethanol Tube | Clear Labs, Inc. | Empty | N/A | 1 | Tube |
| C-10074 | Empty Tube | Empty Tube | N/A | N/A | 8 | Tube |
| Item # | Item Description | Components | Vol, ul | Conc | Qty | UOM |
| CLDX-K200 | Clear DX Reagent Kit 2 | | | | 1 | Kit |
| CLDX-K200-101 | RT-MM Tube | NEB Reverse Transcript Enzyme Master Mix | 800 | 2X | 4 | Tube |
| CLDX-K200-102 | Enzyme PCR1 Tube | TFS Platinum II HS Master Mix | 650 | 2X | 4 | Tube |
| Item # | Item Description | Components | Vol, ul | Conc | Qty | UOM |
| CLDX-K300 | Clear DX Reagent Kit 3 | | | | 1 | Kit |
| CLDX-K300-101 | SPRI Beads Tube | Beckman Coulter AMPure XP | 500 | N/A | 4 | Tube |
| Item # | Item Description | Components | Vol, ul | Conc | Qty | UOM |
| CLDX-K400 | Clear DX SARS-CoV-2 Index 1 Kit | | | | 1 | Kit |
| CLDX-K400-101-001 | PCR1 primers-Row 1 | Clear Labs SARS-CoV-2 Primer Set - Row 1 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-002 | PCR1 primers-Row 2 | Clear Labs SARS-CoV-2 Primer Set - Row 2 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-003 | PCR1 primers-Row 3 | Clear Labs SARS-CoV-2 Primer Set - Row 3 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-004 | PCR1 primers-Row 4 | Clear Labs SARS-CoV-2 Primer Set - Row 4 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-005 | PCR1 primers-Row 5 | Clear Labs SARS-CoV-2 Primer Set - Row 5 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-006 | PCR1 primers-Row 6 | Clear Labs SARS-CoV-2 Primer Set - Row 6 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-007 | PCR1 primers-Row 7 | Clear Labs SARS-CoV-2 Primer Set - Row 7 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-008 | PCR1 primers-Row 8 | Clear Labs SARS-CoV-2 Primer Set - Row 8 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-101 | MM PCR2-ONT 1 | TFS Platinum II HS MM + ONT Barcode 1 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-102 | MM PCR2-ONT 2 | TFS Platinum II HS MM + ONT Barcode 2 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-103 | MM PCR2-ONT 3 | TFS Platinum II HS MM + ONT Barcode 3 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-104 | MM PCR2-ONT 4 | TFS Platinum II HS MM + ONT Barcode 4 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-105 | MM PCR2-ONT 5 | TFS Platinum II HS MM + ONT Barcode 5 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-106 | MM PCR2-ONT 6 | TFS Platinum II HS MM + ONT Barcode 6 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-107 | MM PCR2-ONT 7 | TFS Platinum II HS MM + ONT Barcode 7 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-108 | MM PCR2-ONT 8 | TFS Platinum II HS MM + ONT Barcode 8 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-109 | MM PCR2-ONT 9 | TFS Platinum II HS MM + ONT Barcode 9 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-110 | MM PCR2-ONT 10 | TFS Platinum II HS MM + ONT Barcode 10 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-111 | MM PCR2-ONT 11 | TFS Platinum II HS MM + ONT Barcode 11 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-112 | MM PCR2-ONT 12 | TFS Platinum II HS MM + ONT Barcode 12 | 18 | Proprietary | 1 | Well/Plate |
| Item # | Item Description | Components | Vol, ul | Conc | Qty | UOM |
| CLDX-K500 | Clear DX SARS-CoV-2 Index 2 Kit | | | | 1 | Kit |
| CLDX-K500-101-001 | PCR1 primers-Row 9 | Clear Labs SARS-CoV-2 Primer Set - Row 9 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-002 | PCR1 primers-Row 10 | Clear Labs SARS-CoV-2 Primer Set - Row 10 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-003 | PCR1 primers-Row 11 | Clear Labs SARS-CoV-2 Primer Set - Row 11 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-004 | PCR1 primers-Row 12 | Clear Labs SARS-CoV-2 Primer Set - Row 12 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-005 | PCR1 primers-Row 13 | Clear Labs SARS-CoV-2 Primer Set - Row 13 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-006 | PCR1 primers-Row 14 | Clear Labs SARS-CoV-2 Primer Set - Row 14 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-007 | PCR1 primers-Row 15 | Clear Labs SARS-CoV-2 Primer Set - Row 15 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K500-101-008 | PCR1 primers-Row 16 | Clear Labs SARS-CoV-2 Primer Set - Row 16 | 40 | 125 - 750 nM | 1 | Well/Plate |
| CLDX-K400-101-101 | MM PCR2-ONT 1 | TFS Platinum II HS MM + ONT Barcode 1 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-102 | MM PCR2-ONT 2 | TFS Platinum II HS MM + ONT Barcode 2 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-103 | MM PCR2-ONT 3 | TFS Platinum II HS MM + ONT Barcode 3 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-104 | MM PCR2-ONT 4 | TFS Platinum II HS MM + ONT Barcode 4 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-105 | MM PCR2-ONT 5 | TFS Platinum II HS MM + ONT Barcode 5 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-106 | MM PCR2-ONT 6 | TFS Platinum II HS MM + ONT Barcode 6 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-107 | MM PCR2-ONT 7 | TFS Platinum II HS MM + ONT Barcode 7 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-108 | MM PCR2-ONT 8 | TFS Platinum II HS MM + ONT Barcode 8 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-109 | MM PCR2-ONT 9 | TFS Platinum II HS MM + ONT Barcode 9 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-110 | MM PCR2-ONT 10 | TFS Platinum II HS MM + ONT Barcode 10 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-111 | MM PCR2-ONT 11 | TFS Platinum II HS MM + ONT Barcode 11 | 18 | Proprietary | 1 | Well/Plate |
| CLDX-K400-101-112 | MM PCR2-ONT 12 | TFS Platinum II HS MM + ONT Barcode 12 | 18 | Proprietary | 1 | Well/Plate |

Additional Materials Required and Provided

| Item | Manufacturer | Storage conditions | Clear Labs Part Number | Quantity |
|----------------------------------|------------------------------|--------------------|------------------------|-------------------|
| MinION Flow Cell | Oxford Nanopore Technologies | 2 – 8 °C | R-10023 | 1 |
| RNA Sample Plate, White Barcoded | 4titude | Room temp. | C-10080 | 1 |
| Hamilton lid cover | Hamilton Robotics | Room temp. | C-10012 | Case of 50 plates |
| Clear plate, Non-Barcoded | 4titude | Room temp. | C-10010 | Case of 50 plates |
| Clear plate, barcoded | 4titude | Room temp. | C-10009 | Case of 50 plates |
| 50 µL CO-RE Filter Tips | Hamilton Robotics | Room temp. | C-10028 | Case of 5760 tips |
| 300 µL CO-RE Filter Tips | Hamilton Robotics | Room temp. | C-10013 | Case of 5760 tips |

Special Instrumentation Required (but not Provided)

The Clear Dx™ SARS-CoV-2 Test is to be used with the Clear Dx™ system (# 51160-01) with the Venus 4 version software.

The system includes:

1. Hamilton STAR robotic workstation
2. Hamilton On-Deck Thermal Cyclers (2)
3. Oxford Nanopore GridION Sequencer - MinKNOW 18.12.4
4. ALPAQUA Magnum FLX on deck magnet

This instrumentation is not included with the test kit. Listed below are the equipment and hardware specifications for the Clear Dx™ System and other hardware accessories that are part of the system.

Clear Dx™ Hardware Specifications:

| Specification | Required Configuration |
|---------------------------|--|
| Delivered Hardware System | Clear Dx™ documentation package, Hamilton STAR with instrument bench, ONT GridION, MicroTik Ethernet router, Microcentrifuge |

Hamilton STAR Hardware Specifications:

Technical

| | |
|--|--|
| Dimensions of Hamilton STAR (W x H x D) | 65.5 in. x 35.5 in. x 31.2 in. |
| Dimensions of Hamilton Star Bench (W x H x D) | 65.5 in. x 28.7 in. (32.2 in. with casters) x 31.2 in. |
| Weight of Hamilton Star | 145kg (319 lbs.) |
| Weight of Hamilton Star Bench | 68kg (150 lbs.) |
| Hamilton Consumables Included for Installation | |
| Tips for Star | Part No: 235903 - 300µL Filter tips - CORE FILTER TIPS 300µL, 5760/CS - Quantity 1 Part No: 235948 - 50µL Filter tips - CORE FILTER TIPS 50µL COND PK/5760 - Quantity 1 |
| PCR Consumables | Part No: 814300 - Hamilton PCR Comfort Lids - 50 plates per case - Quantity 1 |
| Optional Hardware - APC Smart-UPS SRT 2200VA | |
| Brand | APC |
| Manufacturer | APC |
| Model | 2200VA |
| Product Line | APC Smart-UPS SRT |

Additional Materials and Reagents Required (but not Provided)

- Cole-Parmer C1008-B Microcentrifuge, Catalog # UX-17701-11 or equivalent
- Vortex Genie-2, from Stellar Scientific, Catalog # SI-0236 or equivalent
- 100% absolute ethanol, from VWR, Catalog # EM-4455S or equivalent
- Twist Synthetic SARS-CoV-2 RNA Control 2 (Accession # MN908947.3; Catalog # 102024)

- Molecular grade PBS buffer (Gibco DPBS, no Ca²⁺ no Mg²⁺, Catalog # 14-190-144 from Fisher Scientific)
- MagMAX Viral RNA Isolation Kit (Catalog # AM1939 from Thermo Fisher Scientific)
- DynaMag-2 Magnet for manual RNA extraction using MagMAX kits (Catalog # 12321D from Thermo Fisher Scientific)

Procedures

Clear Dx™ System Setup and Initialization


Prior to setting up the Clear Dx™ system for running the test, the frozen reagents are thawed to room temperature. Clear Dx™ automation software includes a user- friendly interface. The interface guides the operator step by step during sample and reagent loading with multiple dialogues and interactive images. Different reagent tubes of the kit are numbered and color-coded with the same numbers and colors on the automated system as well as on the user interface. Once all the reagents are loaded and before the automated workflow starts, the system runs a verification step to make sure that all reagents and consumables are loaded correctly. If the operator had loaded a wrong reagent or a reagent in a wrong position, the system would give an alert and provide the user with the instructions to correct the error.

Specimen Collection, Transport and Storage

- ✓ The clinical specimens can be collected either in Universal Transport Medium (UTM), Viral Transport Medium (VTM), PBS buffer or normal saline or equivalent. The collection media are not included in the test kit.
- ✓ Swab specimens from patients are collected in 1-3 mL tubes containing any of the aforesaid transport media at the collection site and are immediately refrigerated upon collection (2 to 8°C). Nasopharyngeal wash/aspirate, nasal aspirate, and bronchoalveolar lavage specimens similarly should be immediately refrigerated upon collection (2 to 8°C). Note: All specimens must be shipped in accordance with applicable national, international, and regional transportation regulations
- ✓ If the specimens cannot be tested within 72 hours of collection, they should be frozen at -80°C until tested.

Sample Registration in the Clear View Application

The Clear View interface for Laboratories:




Navigate the icons on the left side of the application to access the various features.



Lab Overview - View and manage the users and their privileges within your laboratory.




Sample View - Create samples, and view a list of registered samples.




Rack View - View and create virtual racks of samples that will be processed in the Clear Dx™ System.




Test Run View - View completed test runs and results.




Product View - Create products and assign test specificities to facilitate the sample registration process.




Clients View - View and manage Laboratory Clients.



Result Analytics View - View subtypes and groupings.



Notifications - View notifications related to test runs and result availability



User Avatar - View account info, created user accounts, resources, and logout

Company, Client, and User Creation and Management

Company Creation


Your Clear Labs Field Application Scientist will assist you with the Company and Client (Laboratory Client) creation process.

To Manage Existing Clients:

1. Click the “Clients” icon in the left bar. This will display the list of Clients the laboratory has created.

| Client Name | Samples | Positives | Last Run |
|--|---------|-----------|--------------|
| Client Serotype edited | 69362 | 9387 | Aug 15, 2019 |
| ClientN | 15579 | 1931 | Jun 28, 2019 |
| ClientP | 2922 | 446 | Jul 29, 2019 |
| client ten twelve client ten twelve c... | 2596 | 615 | Apr 15, 2019 |
| ClientQ1 | 240 | 0 | Feb 1, 2019 |

2. Select a client to make any changes to their profile or to deactivate their account.




To Add a Client:

1. Click the “+” icon on the top right of the Clients page.
2. Enter the required information in the Product Details.
3. Select the default tests that will populate when products are created for this Client.


User Creation (Clear Labs Admin level only)

Click on the Lab Overview icon to view existing users within the laboratory.




Begin the user creation process by clicking “Add” near the top of the screen.

Complete the fields for name and email address. The added user will be notified via email to complete the registration process.



Privilege Management

Administrators are able to manage permissions for each individual within the company. You can do so within the Users page that was used to create users. Click your user avatar icon near the bottom left of the screen, select the user, and modify their privileges accordingly (if you have permission to do so.) You can choose to alter the Role of a user, which will enable or disable a predefined set of actions or choose specific permissions you would like that user to have. Be wary of changing permissions on your own account, as authorization conflicts may lock you out of your account.



Logging In

Once an account is created for a user, the created user will receive an e-mail supporting them through a final creation of and logging into the account.


Product (Specimen Type) Creation

Registering products for Laboratory Clients is a one-time process that allows the laboratory to capture sample metadata so that results associated with a particular product (i.e. specimen) types (e.g. nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate swab, nasopharyngeal wash/aspirate, nasal aspirate, and bronchoalveolar lavage specimens) can be tracked over time. Additionally, the product creation process is an opportunity to assign the test settings to particular products. The entire process facilitates the sample creation and registration process.

Creating a product (specimen type)

Lab Administrators and Techs can create products. In order to register a new product into Clear View,


1. Select the Products page from the navigation bar. This page lists all products created within the system, and the client they are associated with.
2. Click the green plus icon to begin the product creation process.



3. Name the product (specimen type).
4. Select the Client.
5. Assign a product category.

Target Selection

You will then be guided to Target Selection, where you are able to define what analyses the particular product will undergo. Clear Dx™ currently accommodates SARS-CoV-2 screening and subtyping by default.




Sample Creation

Samples can be created by the laboratory for Laboratory Clients.

Sample Intake

1. Select the Samples page on the navigation bar. Within this page, you are able to view all samples created in the past and create new ones for upcoming test runs.



2. Click the green plus icon on the top right to begin the sample creation process.

Manual sample creation

The screenshot shows a 'Sample Registration' form with the following data:

| | | | |
|-----------------|--------------------|-----------------------|---------------|
| Client | Automation testing | Product | Test Building |
| Lab Sample ID | 123456 | Test | SARS-CoV-2 |
| Date Registered | 09/02/2020 | Date Sample Collected | 09/01/2020 |
| | | Sampling Location | Omaha, NE |

Buttons at the bottom: Duplicate, Delete, Add, Register.

1. Enter the Laboratory Client ID
2. Enter the Product associated with that client.
3. Enter the Lab Sample ID
4. Enter additional details as desired.
5. Click the “Add” button to add more samples. Alternatively, click the “Duplicate” button to duplicate the sample. This is helpful and efficient if the additional samples share many of the same properties. Be sure to update the dissimilar sample information (i.e., Lab Sample ID) accordingly.

Importing Multiple Samples

In the Sample Registration Screen,

1. Select “Import Samples” at the top right of the screen and select the “Import Samples” option to import a list of samples originating from an external LIMS system.
2. Upload a .csv file containing a list of samples you wish to be imported into Clear View.

Example:


| | A | B | C | D | E | F |
|---|-------------|---------------|--------------|-----------------|-----------------------|-------------------|
| 1 | Client Name | Lab Sample ID | Product Name | Date Registered | Date Sample Collected | Sampling Location |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| 6 | | | | | | |

The .csv file must contain the following headers:

- i. Client Name

- ii. Lab Sample ID
- iii. Product Name
- iv. Date Registered
- v. Date Sample Collected
- vi. Sampling Location

3. Clear View will then ask you to match the headers found within the .csv file with those known to the software. Minimally, the .csv should contain identifying metadata such as Client Name, Lab Sample ID, and Product Name (i.e. Specimen Type).




4. Click "Complete" to finish importing the samples list. Once successful, the samples that have been imported may be registered.


Sample Rack Creation

In order for the Clear Dx™ System to accept samples, samples must first be assigned to a "rack" in Clear View. A rack in Clear View captures the physical 96-well 1-D barcoded RNA sample tray (part number C-10080) and the order and arrangement of samples in the tray that will be loaded into the Clear Dx™ System. A Laboratory Technician can create Sample Racks:


1. Select the Racks page on the navigation bar. The screen will display a list of racks that are pending analysis.



2. Click the green plus icon on the top right to begin the Sample Rack creation process.
3. A list of registered samples for the selected target genus are displayed. Add samples to the rack in a manner that represents the physical layout of the 96-well RNA sample plate, which is manually prepared following extraction (see Sample Preparation below).




- Enter Rack ID. The rack ID can be found on the right hand side of the RNA sample tray (see red box below).



- Once all samples have been selected, click “Confirm Rack,” and you will be given a confirmation of the samples that will be included on this Sample Rack. You also have the ability to print the layout of the sample rack for reference by clicking the green download icon.

Rack ID: 7000199807
 Suffix: 2019_08_23_01
 Customer: CL-PM
 Lab: PM Lab1
 Printed Date: Aug 23, 2019, 3:08 PM



| | | | | | | | | | | | | |
|---|-------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| A | ¹ 1096 | ⁹ 1088 | ¹⁷ 1080 | ²⁵ 1072 | ³³ 1064 | ⁴¹ 1056 | ⁴⁹ 1048 | ⁵⁷ 1040 | ⁶⁵ 1032 | ⁷³ 1024 | ⁸¹ 1016 | ⁸⁹ 1008 |
| B | ² 1095 | ¹⁰ 1087 | ¹⁸ 1079 | ²⁶ 1071 | ³⁴ 1063 | ⁴² 1055 | ⁵⁰ 1047 | ⁵⁸ 1039 | ⁶⁶ 1031 | ⁷⁴ 1023 | ⁸² 1015 | ⁹⁰ 1007 |
| C | ³ 1094 | ¹¹ 1086 | ¹⁹ 1078 | ²⁷ 1070 | ³⁵ 1062 | ⁴³ 1054 | ⁵¹ 1046 | ⁵⁹ 1038 | ⁶⁷ 1030 | ⁷⁵ 1022 | ⁸³ 1014 | ⁹¹ 1006 |
| D | ⁴ 1093 | ¹² 1085 | ²⁰ 1077 | ²⁸ 1069 | ³⁶ 1061 | ⁴⁴ 1053 | ⁵² 1045 | ⁶⁰ 1037 | ⁶⁸ 1029 | ⁷⁶ 1021 | ⁸⁴ 1013 | ⁹² 1005 |
| E | ⁵ 1092 | ¹³ 1084 | ²¹ 1076 | ²⁹ 1068 | ³⁷ 1060 | ⁴⁵ 1052 | ⁵³ 1044 | ⁶¹ 1036 | ⁶⁹ 1028 | ⁷⁷ 1020 | ⁸⁵ 1012 | ⁹³ 1004 |
| F | ⁶ 1091 | ¹⁴ 1083 | ²² 1075 | ³⁰ 1067 | ³⁸ 1059 | ⁴⁶ 1051 | ⁵⁴ 1043 | ⁶² 1035 | ⁷⁰ 1027 | ⁷⁸ 1019 | ⁸⁶ 1011 | ⁹⁴ 1003 |
| G | ⁷ 1090 | ¹⁵ 1082 | ²³ 1074 | ³¹ 1066 | ³⁹ 1058 | ⁴⁷ 1050 | ⁵⁵ 1042 | ⁶³ 1034 | ⁷¹ 1026 | ⁷⁹ 1018 | ⁸⁷ 1010 | ⁹⁵ 1002 |
| H | ⁸ 1089 | ¹⁶ 1081 | ²⁴ 1073 | ³² 1065 | ⁴⁰ 1057 | ⁴⁸ 1049 | ⁵⁶ 1041 | ⁶⁴ 1033 | ⁷² 1025 | ⁸⁰ 1017 | ⁸⁸ 1009 | ⁹⁶ 1001 |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |

Publishing, Reporting and Result Analytics

A notification will be sent to the laboratory users when results are available.

Sample Preparation

For each sample, 400µL can be processed through a manual RNA extraction process using the MagMAX Viral RNA Isolation Kit (Catalog # AM1939). The total viral RNA from the virus particles of SARS-CoV-2 present in the nasopharyngeal (NP) swab, oropharyngeal (OP) swab, anterior nasal swab, mid-turbinate swab, nasopharyngeal wash/aspirate, nasal aspirate, or bronchoalveolar lavage (BAL) specimens is co-extracted alongside any human RNA present in the clinical specimen. The final expected elution volume for the extracted RNA is 50µL. Once the Clear Dx™ system is setup and initialized to perform the test, 20µL (only 6 µL total is used for the reaction) of extracted RNA in elution buffer of each of the registered samples is manually loaded into individual wells of the 96-well skirted PCR plates (RNA sample plate, #C10080) provided with the test kit. The plates are then placed in their respective positions in the Clear Dx™ system. Each Clear Dx™ SARS-CoV-2 Test run can process up to two 96-well plates; 192 samples, including controls.

Instrument Maintenance Check

Perform the steps in this section prior to using the Clear Dx™ System.

1. If not already on, turn on all hardware: The Clear Dx™ System, GridION sequencer, On-Deck Thermocycler controllers (ODTC), Plate/tube scanner, desktop computer and monitor.
2. Open the Microlab STAR Maintenance icon on your computer.
3. Check the box for either daily or weekly maintenance. *Note: The Weekly Check overrides the Daily Check.*
4. Click the Run Process icon (green arrow) near the top.
5. At the prompt to perform deck and tip waste maintenance, click Yes
6. At the prompt for carrier maintenance, click OK. (This prompt only appears during the Weekly Maintenance process.)
7. Clean the deck with sanitizing wipes, then click OK.
8. Empty and clean the tip waste, then click OK. *Note: This step is only necessary when the tip waste is full (or close to full) and can be done at any time between runs.*
9. At the prompt to check the channel tightness, click Yes. This verifies the integrity of the O-rings, and takes about two minutes. *Note: If a failure message occurs, discontinue usage and contact Clear Labs for service.*
10. At the prompt to check Capacitive Liquid Level Detection, click Yes (This tests the machine's ability to detect liquids) *Note: If a failure message occurs, discontinue usage and contact Clear Labs for service.*
11. Once the last check concludes, click OK, then exit the program. You can now proceed to loading the Clear Dx™ System.

Instrument Setup and Loading

The Clear Dx™ System is designed to accommodate and process as many as 190 clinical specimens in a single run, in addition to a single positive and a single negative control per run (192 samples total per run). Up to two 96-well PCR barcoded RNA sample plates can be loaded onto the instrument at a time, and each sample plate will be loaded with the corresponding number of consumables illustrated in the matrix below:

| Item | Description | Plates Needed for up to 96 samples | Plates Needed for >96 and up to 192 samples |
|--|---|------------------------------------|---|
| RNA Sample Plate | Plate used to load extracted RNA into Clear Dx™ instrument. White in color. | 1 | 2 |
| PCR 1 Plate | Plate used for primary PCR. Clear in color. | 1 | 2 |
| RT Plate | Plate used to carry out RT PCR. Clear in color. | 1 | 2 |
| Hamilton Lid Cover | Lid to contain reactions. Clear in color. | 1 | 2 |
| Cover Plate | Plate used to provide contamination-free lid parking. Clear in color. | 1 | 2 |
| PCR 2 Plate | Plate used for secondary PCR. Clear in color. | 1 | 1 |
| Reagent Plate | Plate used to mix reagents. Clear in color. | 1 | 1 |
| 50 µL CO-RE Filter Tips | Pipette tips to be used with Hamilton Star platform. | Stock completely | Stock completely |
| 300 µL CO-RE Filter Tips | Pipette tips to be used with Hamilton Star platform. | Stock completely | Stock completely |
| MinION Flow Cell | Flow cell to be used for sequencing | 1 | 1 |
| Clear Dx™ Reagent Kit 1 | Library preparation kit | 1 | 1 |
| Clear Dx™ Reagent Kit 2 | Sample Processing kit | 1/2 | 1 |
| Clear Dx™ Reagent Kit 3 | Library clean up kit | 1 | 1 |
| Clear Dx™ SARS-CoV-2 Index 1 Kit and 2 kit | Index plates | One index plate | Two index plates |

For efficiency purposes, it is ideal to populate a sample plate with as many samples as possible before including additional plates. The following instructions assume that one 96-well sample plate is being processed.

Loading the Clear Dx™ System is an easy-to-follow process guided by a series of prompts. Simply follow the prompts on the Clear Dx™ system interface screen to complete the process.

Note: The current configuration of the Clear Dx™ system cannot accept fewer than 48 samples per run. If fewer than 48 samples are being loaded into the system, it is required that “blank” samples be added to both the virtual sample carrier and the physical sample carrier to make up the difference. The Clear Dx™ system will report an error if fewer than 48 samples are detected in the sample carrier.

Preparation

1. Before each run, remove the required tubes, as requested by the software user interface, from Reagent Kits I, II, III, and a Flow Cell from appropriate storage conditions and bring them to room temperature. (Remove the Flow Cell from the bag and place it on a level surface). Thirty minutes at room temperature is recommended.
2. Remove Tube #13 and #14 from Reagent Kit I and fill each tube with 2 mL of 100% absolute ethanol (not supplied).
3. If present, remove all the used consumables from the previous run to be ready for loading fresh consumables. Clean up any liquid spill and disinfect the robot surface by wiping down with Isopropyl alcohol wipes.
4. Open the “Clear Dx™” application on Clear Dx™ System interface.
5. A “Get Ready Screen” will be displayed. Follow the on-screen instructions to complete the required steps and confirm that each step was completed successfully when prompted. Continue the process for each screen that follows.

Note: Open the door to load the Clear Dx™ System.

Load Samples and Controls

Follow the on-screen prompts to load the RNA sample plates. The number of plates and samples onboard will inform the Clear Dx™ System how many reagent sets need to be loaded in subsequent steps. Proceed to the next step when complete.

Load Flow Cell

1. When prompted, retrieve the now room temperature flow cell and load it into slot X1 on the GridION sequencer.
 - a. Remove Flow Cell from packaging, retain the packaging.
 - b. Orient the Flow Cell so the yellow window faces the rear.
 - c. Insert it at an angle until you feel the rear end catch, then set down the front end.
 - d. When secure and connected, the “X1” light will turn green.

Note 1: Keep the Flow Cell as level as possible to avoid introduction of air bubbles

Note 2: Be careful not to bend the bottom pins of the flow cell.

2. Gently rotate the priming gate 90° clockwise, using the thumb as the fulcrum.
Note: Be careful not to over-rotate.
3. Remove the Flow cell port’s cover and retain.
4. Clean the stainless steel plug with lint-free wipes.
5. Install plug into the Flow cell port. Gently push down the plug until secure, making sure there’s no free movement.
6. Click “Flow Cell QC” to begin the quality check (a 7-minute process). Follow the prompts as they are displayed. While the Flow Cell is undergoing QC check, the remaining loading steps are completed.

Note: If the Flow Cell fails, do the following:

1. Remove it from the GridION sequencer and close the priming gate fully by rotating clockwise
2. From the waste port located at the end of the waste reservoir, fully aspirate the contents within the Flow Cell
3. Place the included sticker on the top face of the Flow Cell and place back in the plastic housing
4. Insert into the original sealing bag and seal securely. Contact Clear Labs service to coordinate return and replacement of the Flow Cell.

Load Plates

Follow the prompts to load the two Index plates, Lid and Cover into their designated locations.

Note: All plates are loaded with well A1 to the top left, barcodes on the right side.

Load Tips

Follow the prompts to load the Tips into the Tip Carriers until both are fully stocked.

1. Fill the left side with 50 μ L Tips (the racks will have pink barcodes).
2. Fill the right side with 300 μ L Tips (the racks will have yellow barcodes).

Note: Unused tips from previous runs can be loaded. Make sure to use aseptic technique when performing a transfer and take care not to mix different sized tips with a rack. Clear Dx™ System does not track tip inventory. Tips are consumed from the back rack first, moving forward.

Load Reagent Tubes

For convenience, reagents from Kit I, Kit II, and Kit III are numbered for their respective locations on the sliding racks on the instrument deck. Clear Dx™ System will calculate the required reagents according to the number of samples.

1. Using a microcentrifuge, give all tubes with reagents and index plate(s) a 1-2 sec spin.
2. Vortex the “SP” tubes for 20 seconds before loading.
3. Follow the prompts to scan the reagent kits into the system.

Complete Flow Cell QC Check

The Flow Cell QC check started in the “Load Flow Cell” section should be complete. Follow the onscreen prompts to continue.

Pre-Run Check

Begin the Pre-Run Check when prompted and follow the onscreen instructions.

Note: Close door before beginning Pre-Run Check

Once the Pre-Run Check finishes, click “Confirm”.

Secure Index Plate(s)

Follow the prompts to secure the Index Plate by installing its Down Holder. Click “Continue” to proceed.

1. Open door. Make sure the corner pins of the holder are facing upward.
2. Click “Continue”.


Start Test Run

1. Close the door.
2. Click “Start Test Run” to begin the automated testing process, which should take 8-9 hours
3. Once the run concludes, click “OK” at the final screen.


Data Analysis

Results Access


Samples View - click an individual sample to see the result details.



Runs View - View a list of test runs.



Select a run to view the samples and higher level results.




A “Negative” result is displayed when the targeted analyte is not detected in the sample.

A “Positive” result is displayed when the target is detected in the sample.

An “Invalid” result is generated when the built-in internal control technologies detect an unsuccessful reaction. Contact Clear Labs for further support.

Select an individual sample to see additional details.



Reporting Clear Dx™ Results

Results for a Clear Dx™ run can be exported from the Run Details page in the Clear View application as a .csv file by clicking on the Download icon near the top right side of the browser window. Use this feature if results need to be uploaded into a laboratory information management system (LIMS) for communication to other parties. An example report is pasted below.

| Rack | Well | Lab Sample ID | Clear ID | Client Name | Product Name | Target Result | Target Virus | Date Sample Collected | Run Complete | Sampling Location |
|------|------|---------------|-----------------|-------------|--------------|---------------|--------------|-----------------------|----------------|-------------------|
| 1 | A01 | 12345-1 | CL-A0-0006-1222 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | B01 | 12345-2 | CL-A0-0006-1221 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | C01 | 12345-1 | CL-A0-0006-1220 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | D01 | 12345-2 | CL-A0-0006-1219 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | E01 | 12345-1 | CL-A0-0006-1218 | Lab A | NP Swab | NEGATIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | F01 | 12345-2 | CL-A0-0006-1217 | Lab A | NP Swab | NEGATIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | G01 | 12345-1 | CL-A0-0006-1216 | Lab A | NP Swab | NEGATIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | H01 | 12345-2 | CL-A0-0006-1215 | Lab A | NP Swab | NEGATIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | A02 | 12345-1 | CL-A0-0006-1214 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | B02 | 12345-2 | CL-A0-0006-1213 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | C02 | 12345-1 | CL-A0-0006-1212 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |
| 1 | D02 | 12345-2 | CL-A0-0006-1211 | Lab A | NP Swab | POSITIVE | SARS-CoV-2 | 8/9/2020 | 8/11/2020 7:33 | Omaha, NE |

The report includes the following information:

Title – The Run ID associated with the report.

Rack – The sample plate number. The Clear Dx™ system can accept up to two plates of samples.

Well – The sample position in the sample plate. Sample plates are 8x12 arrays with letters indicating rows, and numbers indicating columns.

Lab Sample ID – The unique identifier assigned by a laboratory to a sample.

Clear ID – The unique identifier assigned by the Clear Dx™ system to a sample.

Client Name – Laboratory-designated description that can be used to differentiate sample owners.

Product Name – Laboratory-designated description that can be used to differentiate sample types.

Target Result – Positive, Negative, or Invalid.

Target Virus – The target analyte.

Date Sample Collected – optional field for capturing the date sample was collected.

Run Complete – Date/time stamp for run completion.

Sampling Location – Optional field for capturing the geographical origin of the sample.

Post Processing Procedures

Emptying the Clear Dx™ System

Flush Flow Cell

1. Remove Flow Cell and prepare to flush.
 1. Replace the retained plastic SpotOn port cover.
 2. Hold Flow Cell over a receptacle containing a solution of 10% bleach.
 3. Dispense 4 mL of DI water into the priming port.



4. Close priming port by turning gate counter clockwise.


5. Remove excess liquid from waste channel.



6. Return flow cell to tray. Apply the original plastic snap to close the spotON port.



7. Place sealed flow cell tray back into pouch and close zippered pouch.



8. Store sealed, flushed Flow Cells at room temperature. Contact Clear Labs service to arrange return shipping.

Remove & Dispose Consumables

Empty tip racks can be removed at this time and partial racks can be consolidated. Be sure to use aseptic technique when handling unused pipette tips and take care not to mix different sized tips within a rack.

The following items should be treated as biohazards:

- RNA sample plates (white)
- RT PCR plates (Clear)
- PCR plates (Clear)
- Reagent tubes
- Used sample plates
- Tip waste bag
- Reagent Plate (clear)

The following items potentially contain nucleic acids and need to be neutralized upon removal. Some of them also have ethanol in them. The suggested method is to submerge the listed items in 10% bleach or a DNase for 30 minutes before disposal (not autoclaved) as hazardous waste.

- Kit 1, tubes 1, 13 and 14 (neutralize with a DNase - not bleach)
- Waste tubes (1-8) on Rack 2 (neutralize with a DNase - not bleach)
- PCR covers
- PCR Plates (clear)
- Cover plate (clear)

Technical Support

For questions or comments, please contact your Clear Labs Field Application Scientist. You can also email service@clearlabs.com

Quality Control

The following controls are used in Clear Dx™ SARS-CoV-2 Test for ascertaining the validity of the sample, assay and run. The validity of these controls are factored into making the final calls for the samples.

- A **“No template” (negative) control (NTC)** is needed to verify the absence of viral template contamination in all reagents of all steps of the workflow to monitor false positive signals. This will be accomplished by the use of **molecular grade PBS buffer (Gibco DPBS, no Ca²⁺ no Mg²⁺, Catalog # 14-190-144 from Fisher Scientific)** or equivalent as a negative specimen, alongside other clinical specimens input in the extraction step. This control will be in all assay runs, representing one negative sample irrespective of the total number of clinical specimens run (minimum 48 – maximum 190 clinical specimens/run). This is not provided with the kit.
- A **positive assay control** is needed to verify that the assay run from extracted RNA to result is performing as intended. This is not subjected through any extraction and is included in the test run only after the extraction step. This provides certainty of reverse transcription reaction, robotic liquid handling operations, stability of assay reagents, proper operation of other

ancillary instrumentation such as thermocycler, magnets, etc. on the automation platform and the bioinformatics pipeline and reporting software. To accomplish this, Clear Dx™ uses **Twist Synthetic SARS-CoV-2 RNA Control 2 (Accession # MN908947.3; Catalog # 102024)** diluted by 20,000x to 50,000 copy equivalents/mL (roughly 5x the LoD from extracted RNA). This control is a non-encapsulated product consisting of 6 non-overlapping 5 kb synthetic RNA fragments spanning near the entire viral genome (>99.9%). This control will be in all runs, representing one negative sample irrespective of the total number of clinical specimens run (minimum 48 – maximum 190 clinical specimens/run). This is not provided with the kit.

- An **extraction control or sample quality control** validating that human RNA is present, is needed for clinical samples and is used to determine if the RNA extraction process occurred successfully and the sampling procedure is valid. For this reason, Clear Dx™ SARS-CoV-2 kit includes **barcoded primers for human RNase P** added into each of the barcoded primer set to be used for individual sample. These primers will amplify the human RNase P in all samples and hence will serve as positive extraction control as well as a control for sample quality.
- An **internal control** is needed to verify successful PCR amplification within each sample well. Clear Dx™ SARS-CoV-2 Test uses a synthetic DNA template of 367bp, added in the PCR mix, along with corresponding indexed primers to that target, to conclusively identify that PCR occurred in each well, delineating invalid wells. Internal control is present in all sample wells, including the assay controls. Along with the positive assay control, this also verifies the entire assay in every single well. The internal control template and primers are provided with the test kit in reagent kits CLDX-K100 and CLDX- K400 & K500 respectively.
- In addition to internal control, Clear Dx™ SARS-CoV-2 kit also includes a **sequencing library control**, a synthetic DNA sequence of 600bp length. This is added just prior to sequencing in the assay workflow and is needed to verify the complete processing of the pooled sequencing library. Note that there are no library normalization steps part of the assay. This allows for the identification of errors in sequencing or library preparation. The sequencing library control is added once per sequencing run, present in all runs regardless of the number of clinical specimens completed (minimum 48 – maximum 190 clinical specimens/run).

Interpretation of Results

All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted.

- a) **Negative control:** If a positive result is identified in the NTC of the assay, all positive results in clinical samples must be re-extracted and retested with a new reagent kit. If the NTC well results in a negative viral signal, it can be concluded that no viral template contamination is present.

- b) Positive control: If the positive control well with the viral RNA control does not result in a positive result in a run, then all negative samples in the run cannot be conclusively ruled out for viral presence and they need to be re-tested from their extracted RNA. However, the samples that were called positive, can be declared as positive.
- c) Extraction control (or) Sample quality control: In clinical samples where human RNA is expected to be present, if the extraction control human RNA target does not amplify and does not produce any sequencing reads, and no viral reads are detected, then the sample must be re-extracted and retested or resampled if failed multiple times. A minimum threshold of 10 sequencing reads for RNase P marker is established to call this control “positive”. This threshold has been established based on training data from Nasopharyngeal clinical swab specimens.
- d) Internal control: If any sample well fails to produce less than 100 sequencing reads at the final step of the BIP, including either reads of viral amplicons or internal control but excluding RNase P, then that individual sample and well must be ruled “invalid”, and retested. This threshold of 100 reads was determined based on a large set of training data comprising several runs.
- e) Sequencing library control: If sequencing results have no sequencing library control reads in the run, and no reads for internal control or any of the viral amplicons, it can be concluded that the library preparation or sequencing portion of the Clear Dx™ SARS-CoV-2 assay did not complete. In this instance the user is reported of a sequencing run failure and is prompted to reload all reagents and samples and retest all wells.
- f) Run-level performance control: Along with the Sequencing library control having non-zero reads, the total number of reads in a run that survive past the quality filters should be greater than 200,000 for a run to be considered valid. This threshold has been established based on a large training dataset from our development runs. If a run has < 200,000 reads, the user is reported of a sequencing run failure and is prompted to repeat the run with a new test kit, starting from the extracted RNA.

The acceptance criteria for a valid result for a clinical sample based on all the above controls is shown in the Table below.

| SARS-CoV-2 Detected in Sample* | Internal Control in Sample | Extraction control in Sample | Sample Result | Interpretation | Action |
|--------------------------------|----------------------------|------------------------------|---------------------|-------------------------|--|
| + | Pass | Pass | SARS-CoV-2 Detected | SARS-CoV-2 RNA Detected | Report results to sender and appropriate public health authorities |
| + | Pass | Fail | SARS-CoV-2 Detected | SARS-CoV-2 RNA Detected | Report results to sender and appropriate public health authorities |

| SARS-CoV-2 Detected in Sample* | Internal Control in Sample | Extraction control in Sample | Sample Result | Interpretation | Action |
|--------------------------------|----------------------------|------------------------------|-------------------------|-----------------------------|---|
| + | Fail | Pass | SARS-CoV-2 Detected | SARS-CoV-2 RNA Detected | Report results to sender and appropriate public health authorities |
| + | Fail | Fail | SARS-CoV-2 Detected | SARS-CoV-2 RNA Detected | Report results to sender and appropriate public health authorities |
| - | Pass | Pass | SARS-CoV-2 Not Detected | SARS-CoV-2 RNA Not Detected | Report results to sender and appropriate public health authorities |
| - | Fail | Pass | SARS-CoV-2 Not Detected | SARS-CoV-2 RNA Not Detected | Report results to sender and appropriate public health authorities |
| - | Pass | Fail | Invalid | Invalid Result | Repeat test from extracted RNA. If a second test yields 'Invalid', report results to sender and request a second sample if clinically indicated |
| - | Fail | Fail | Invalid | Invalid Result | Repeat test from extracted RNA. If a second test yields 'Invalid', report results to sender and request a second sample if clinically indicated |

Limitations of the test

- ✓ If Clear Dx™ automation fails for unforeseen reasons like a power failure or ethernet cable malfunction, the entire run fails, and all the RNA used for the test get compromised. For this reason, we always recommend saving the RNA extracts for all the samples in 2-8°C until the results for all the samples have been successfully obtained without being required to repeat.
- ✓ Automated liquid handling requires precise positioning of the robotic arm and for some reasons if the robotic platform gets dislodged from its stable position because of a lab accident or an earthquake, the system must be realigned to its original position. If such an incident happened but went unnoticed, then the specific run may produce erroneous results.
- ✓ False-negative results may arise from degradation of the viral RNA during shipping and storage.
- ✓ As with any molecular test, mutations within the target regions of the Clear Dx™ SARS-CoV-2 Test could affect the primer binding resulting in failure to detect the presence of the virus.
- ✓ Negative results do not preclude infection with the SARS-CoV-2 virus and should not be the sole basis of a patient treatment and management or public health decision. Follow up testing should be performed according to the current CDC recommendations.

- ✓ Typically, RNA may persist even after the virus is no longer viable in the patients. A positive result in Clear Dx™ test indicates just the detection of the SARS-CoV-2 RNA and no claim is made on the viability of the actual virus. However, unlike most assays, Clear Dx™ test looks for several longer regions of the viral genome.
- ✓ Anterior nasal swabs, middle-turbinate swabs, nasal wash or aspirates and bronchoalveolar lavage fluid specimens are additional acceptable respiratory specimens that can be tested with Clear Dx™ SARS-CoV-2 test; however, performance with these specimen types have not been determined.

Conditions of Authorization for Labs

The Clear Dx™ SARS-CoV-2 test Letter of Authorization, along with the along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas>.

However, to assist clinical laboratories using the Clear Dx™ SARS-CoV-2 test, the relevant Conditions of Authorization are listed below:

- ✓ Authorized laboratories* using the Clear Dx™ SARS-CoV-2 test will include with test result reports all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- ✓ Authorized laboratories using the Clear Dx™ SARS-CoV-2 test will use the Clear Dx™ SARS-CoV-2 test as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use the Clear Dx™ SARS-CoV-2 test are not permitted.
- ✓ Authorized laboratories that receive the Clear Dx™ SARS-CoV-2 test will notify the relevant public health authorities of their intent to run the Clear Dx™ SARS-CoV-2 test prior to initiating testing.
- ✓ Authorized laboratories using the Clear Dx™ SARS-CoV-2 test will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- ✓ Authorized laboratories will collect information on the performance of the Clear Dx™ SARS-CoV-2 test and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Clear Labs Technical Support (via email: service@clearlabs.com) any suspected occurrence of false positive or false negative results and significant deviations

from the established performance characteristics of Clear Dx™ SARS-CoV-2 test of which they become aware.

- ✓ All laboratory personnel using the Clear Dx™ SARS-CoV-2 test must be appropriately on the Clear Dx™ system, in the techniques of real-time PCR and NGS and use appropriate laboratory and personal protective equipment when handling this kit, and use the Clear Dx™ SARS-CoV-2 test in accordance with the authorized labeling.
- ✓ Clear Labs, authorized distributors, and authorized laboratories using the Clear Dx™ SARS-CoV-2 test will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

*The letter of authorization refers to, “Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests” as “authorized laboratories.”

Clear Dx™ SARS-CoV-2 Test Performance

Limit of Detection (LoD) - Analytical Sensitivity:

The analytical sensitivity (LoD) of the Clear Dx™ SARS-CoV-2 Test was determined by making serial dilution of Twist Synthetic SARS-CoV-2 RNA Control 2 (Accession # MN908947.3; Catalog # 102024) in pooled negative nasopharyngeal clinical specimens at four different concentrations – 10000 copies/mL, 5000 copies/mL, 2000 copies/mL and 1000 copies/mL, along with 100pg/μL of carrier RNA and testing them through the entire workflow. All the contrived samples at different RNA concentrations were extracted independently using the MagMAX Viral RNA Isolation Kit (Catalog # AM1939) manual workflow as recommended by the manufacturer with 400 μL as the input sample volume and 50 μL as the elution volume. The extracted RNA from all the contrived samples were run together in four replicate runs by four different operators through Clear Dx™ SARS-CoV-2 test.

The results are summarized in the table below. 97% of the detection calls were accurate for the input concentration of 2000 copies/mL RNA in the negative contrived samples. So, the **LoD of Clear Dx™ SARS-CoV-2 is claimed to be 2000 copies/mL in the clinical sample.**

| SARS-CoV-2 Twist RNA (copies/mL) | No. of replicates | Detected as Positive in Clear Dx™ SARS-CoV-2 test | Percent accuracy |
|----------------------------------|-------------------|---|------------------|
| 10000 | 3 | 3 | 100 % |
| 5000 | 27 | 27 | 100% |
| 2000 | 33 | 32 | 97% |
| 1000 | 33 | 27 | 82% |

Results from the experiment to determine analytical sensitivity of the Clear Dx™ SARS-CoV-2 test

Inclusivity:

The inclusivity test was evaluated using *in silico* analysis. In total, 81,375 SARS-CoV-2 genomes were downloaded from GISAID database (<https://www.gisaid.org>, as of August 16, 2020). A preliminary curation was conducted to remove genomes with 1) lengths \leq 29,000 bp; 2) more than 500 bps of ambiguity characters (gaps or N). There were 65,365 genomes left for inclusivity check. A BLASTn (NCBI) analysis was performed to quantify the level of primer homology by querying each of our 21 SARS-CoV-2 primer sequences against the downloaded SARS-CoV-2 genomes. The table below summarizes the homology analysis for all 65,365 SARS-CoV-2 genomes.

| Percent of Primer Pairs Homology | Mean | Median | 5th Percentile | 95th Percentile |
|----------------------------------|--------|--------|----------------|-----------------|
| 100% homology | 98.90% | 99.20% | 97.20% | 99.60% |
| >80% homology | 99.60% | 99.80% | 98.90% | 99.90% |

Summary of homology analysis for all 65,365 SARS-CoV-2 genomes

In silico PCR analysis was conducted to check primers amplification on genomes. The table below shows the frequencies of amplified primer numbers in the curated genomes set. There was not a single genome having fewer than 9 primers amplified *in silico*, which indicated a 100% detection rate in theory with a prediction of high sensitivity.

| Primers amplified number | Genome frequencies |
|--------------------------|--------------------|
| 21 | 61280 |
| 20 | 3450 |
| 19 | 368 |
| 18 | 136 |
| 17 | 69 |
| 16 | 21 |
| 15 | 11 |
| 14 | 15 |
| 13 | 5 |
| 12 | 2 |
| 11 | 1 |
| 10 | 5 |
| 9 | 2 |

| Primers amplified number | Genome frequencies |
|--------------------------|--------------------|
| <9 | 0 |

***In silico* primer amplification profile for the curated genome set**

Cross-reactivity (Exclusivity):

An *in silico* cross-reactivity analysis was performed to assess if the 21 viral primer pairs in the Clear Dx™ SARS-CoV-2 Test have any cross reactivity with the genomes of the microorganisms commonly present in the clinical specimens collected for SARS-CoV-2 tests. A cohort of 62,916 non SARS-CoV-2 genome sequences, compiled from GenBank on 04/20/2020, was considered for this analysis. A BLASTn (NCBI) analysis was then performed to quantify the number of primer pairs with more than 80% homology with each of the genomes in the cohort. The results of the analysis are shown in the table below.

| Organism | Number of genomes (or genome segments) included in analysis | Number of genomes with ≥80% homology to any SARS-CoV-2 viral primers |
|-----------------------------------|---|--|
| Human adenovirus | 615 | 0 |
| <i>Bordetella pertussis</i> | 1257 | 0 |
| <i>Candida albicans</i> | 1 | 0 |
| <i>Chlamydia pneumoniae</i> | 4 | 0 |
| Human coronavirus 229E | 25 | 0 |
| Human coronavirus HKU1 | 39 | 0 |
| Human coronavirus NL63 | 59 | 0 |
| Human coronavirus OC43 | 170 | 0 |
| Human enterovirus | 322 | 0 |
| <i>Haemophilus influenzae</i> | 109 | 0 |
| <i>Homo sapiens</i> | 1 | 1 |
| Influenza A | 55584 | 0 |
| Influenza B | 1939 | 0 |
| <i>Legionella pneumophila</i> | 168 | 0 |
| MERS | 520 | 0 |
| Human metapneumovirus | 156 | 0 |
| <i>Mycobacterium tuberculosis</i> | 354 | 0 |
| <i>Mycoplasma pneumoniae</i> | 153 | 0 |

| Organism | Number of genomes (or genome segments) included in analysis | Number of genomes with ≥80% homology to any SARS-CoV-2 viral primers |
|-----------------------------------|---|--|
| Human parainfluenza virus | 125 | 0 |
| <i>Pneumocystis jirovecii</i> | 15 | 0 |
| <i>Pseudomonas aeruginosa</i> | 381 | 0 |
| Human rhinovirus | 223 | 0 |
| RSV | 9 | 0 |
| SARS-CoV-1 | 268 | 268 |
| <i>Staphylococcus epidermidis</i> | 43 | 0 |
| <i>Streptococcus pneumoniae</i> | 86 | 0 |
| <i>Streptococcus pyogenes</i> | 276 | 0 |
| <i>Streptococcus salivarius</i> | 24 | 0 |

Summary of *in silico* cross-reactivity analysis results

Of the organisms listed above, only SARS-CoV-1 showed ≥ 80% homology to any of the CoV-2 primers. Those primers are shown in the table below along with the number of SARS genomes (out of a total of 268) for which there was evidence of homology (≥ 80%).

| Primer | Number of SARS-CoV-1 genomes with ≥ 80% homology to primer |
|--------|--|
| 10_F | 7 |
| 13_F | 260 |
| 14_R | 268 |
| 20_F | 266 |
| 21_F | 268 |
| 21_R | 268 |

Primers in Clear Dx™ SARS-CoV-2 Test that show homology to SARS CoV-1

Though many SARS-CoV-2 primers show ≥ 80% homology to SARS CoV-1 genomes, the **assay is not expected to produce a false positive** even in the unlikely case of encountering SARS CoV-1. That is because, unlike methods such as qPCR, sequencing allows for the direct comparison of amplicon sequences to both SARS-CoV-1 and SARS-CoV-2 alleles in order to make the proper taxonomic assignment. Primer 21 is designed to include SARS CoV-1 and that is why all the SARS CoV-1 genomes tested have > 80% homology for that primer set. But the amplicon targeted by

these primers has almost 10% difference in their alleles and our BIP can correctly distinguish that. A more detailed study on SARS CoV-1 is presented in the next sub- section.

In addition to the prokaryotic genomes listed above, primer sequences were also aligned against eukaryotic genomes *Candida albicans* and *Homo sapiens* (GRCh38). In some cases, shown in the table below, some primers showed $\geq 80\%$ homology to human chromosomes.

| Primer | Human chromosomes with $\geq 80\%$ homology to primer |
|--------|---|
| 2_R | 1,11,20 |
| 3_F | X |
| 3_R | 1,12,14,16,20 |
| 6_F | 11 |
| 8_F | 14 |
| 11_R | 17 |
| 14_R | 3,7,8,9,11,22 |
| 16_R | 3 |
| 18_R | 20 |

Primers in the Clear Dx™ SARS-CoV-2 Test that show homology to human chromosomes

In 10 of the 20 cases of homology with human chromosomes, there are mismatches at or near the 3' end of the primer that would likely be disruptive to primer extension. Note that any human reads that happen to be present in the sequencing output will be identified as not belonging to SARS-CoV-2 on the basis of sequence composition and will be discarded.

We also performed a wet testing experiment for evaluating cross-reactivity, where 25 microorganisms commonly found in the upper respiratory tract of the humans are tested through the Clear Dx™ SARS-CoV-2 Test starting with their extracted RNA or DNA. RNA or DNA of these microorganisms at appropriate concentrations were tested in duplicates along with positive Twist synthetic RNA controls and negative (NTC) controls in a single 96-plate. The results are reported in the table below. None of these pathogens show any cross-reactivity to the SARS-CoV-2 primers in Clear Dx™ assay.

| Microorganism name | Material used | Source | Catalog # | Conc. tested (Genome equivalents/ μ L) | SARS-CoV-2 detected? |
|-----------------------------|---------------|--------|---------------|--|----------------------|
| <i>Bordetella pertussis</i> | DNA | ATCC | 9797D-5 | 10^6 | No |
| <i>Candida albicans</i> | DNA | ATCC | 10231 (#3147) | 10^6 | No |
| <i>Chlamydia pneumoniae</i> | DNA extract | ATCC | 53592 | 10^6 | No |

| Microorganism name | Material used | Source | Catalog # | Conc. tested (Genome equivalents/ μ L) | SARS-CoV-2 detected? |
|-----------------------------------|---------------|--------|------------|--|----------------------|
| Coronavirus 229 E | RNA | ATCC | VR-740D | 10^5 | No |
| Coronavirus HKU1 | Synthetic RNA | ATCC | VR-3262SD | 10^5 | No |
| Coronavirus NL63 | Synthetic RNA | ATCC | VR-3263SD | 10^5 | No |
| Coronavirus OC43 | RNA | ATCC | VR-1558D | 10^5 | No |
| Enterovirus | RNA | ATCC | VR-1825D | 10^5 | No |
| <i>Haemophilus influenzae</i> | DNA | ATCC | 51907D-5 | 10^6 | No |
| Influenza A H1N1 | RNA | ATCC | VR-1736D | 10^5 | No |
| Influenza B H3N2 | RNA | ATCC | VR-1535D | 10^5 | No |
| <i>Legionella pneumophila</i> | DNA | ATCC | 33152DQ | 10^6 | No |
| MERS Coronavirus | RNA | ATCC | 3248SD | 10^5 | No |
| Metapneumovirus 8 | RNA | ATCC | VR-3250SD | 10^5 | No |
| <i>Mycobacterium tuberculosis</i> | DNA | ATCC | 25177DQ | 10^6 | No |
| <i>Mycoplasma pneumoniae</i> | DNA | ATCC | 25177DQ | 10^6 | No |
| Parainfluenza 1 | RNA extract | ATCC | VR-94D | 10^5 | No |
| Parainfluenza 2 | RNA extract | ATCC | VR-92D | 10^5 | No |
| Parainfluenza 3 | RNA extract | ATCC | VR-93D | 10^5 | No |
| <i>Pseudomonas aeruginosa</i> | DNA | ATCC | 47085DQ | 10^6 | No |
| Rhinovirus 1A | RNA | ATCC | VR-283DQ | 10^5 | No |
| Respiratory Syncytial Virus A | RNA | ATCC | VR-1580DQ | 10^5 | No |
| SARS Coronavirus | Synthetic RNA | Twist | SARS 2003 | 10^5 | No |
| <i>Staphylococcus epidermidis</i> | DNA | ATCC | 12228DQ | 10^6 | No |
| <i>Streptococcus pneumoniae</i> | DNA | ATCC | 700669DQ | 10^6 | No |
| <i>Streptococcus pyogenes</i> | DNA | ATCC | BAA-572D-5 | 10^6 | No |

Summary of the wet testing results of the cross-reactivity study

Microbial Interference Studies:

As explained in the section above, only SARS-CoV-1 has homology to primers/probes of the SARS-CoV-2 in the Clear Dx™ test. But the bioinformatic analysis of Clear Dx™ platform can clearly differentiate the reads based on the allelic difference of the sequences if they are one or the other.

We performed a microbial interference study by adding synthetic SARS CoV-1 RNA (10^7 genome equivalents/mL) from Twist Bioscience to SARS-CoV-2 synthetic RNA (Accession # MN908947.3; Catalog # 102024) at 10,000 (~5x LoD) & 100,000 genome (~50x LoD) equivalents/mL. We did not

observe any degradation of detection calls of SARS-CoV-2 because of the addition of SARS CoV-1. The results are summarized in the table below.

| Sample | # of replicates | SARS-CoV-2 detected? |
|---|-----------------|----------------------|
| SARS-CoV-2 RNA (100,000 copies/mL) | 3 | Yes |
| SARS-CoV-2 RNA (10,000 copies/mL) | 3 | Yes |
| SARS CoV-1 RNA (10 ⁷ copies/mL) | 3 | No |
| SARS-CoV-2 RNA (100,000 copies/mL) + SARS CoV-1 RNA (10 ⁷ copies/mL) | 3 | Yes |
| SARS-CoV-2 RNA (10,000 copies/mL) + SARS CoV-1 RNA (10 ⁷ copies/mL) | 3 | Yes |

Summary of the microbial interference study with SARS CoV-1

Endogenous Interference Substances Studies:

Clear Dx™ SARS-CoV-2 Test uses RNA extracted from standard, well-established extraction methods as discussed in the earlier sections. The assay is not expected to experience any impact from any potential interfering substances.

Clinical Performance Evaluation:

Clinical evaluation was performed by directly comparing the results of Clear Dx™ SARS-CoV-2 Test against a Real-Time Reverse Transcriptase (RT) PCR Diagnostic authorized by the FDA for Emergency Use Authorization on the samples provided by the same lab as described below.

50 positive and 32 negative clinical nasopharyngeal (NP) patient specimens either in viral transport media (VTM) or sterile saline buffer were procured. RNA from these clinical samples were extracted using the manual workflow with MagMAX Viral RNA Isolation kit (Catalog #AM1939). The specimen volume processed was 400 µL for all the samples and the elution volume was 50µl. The extracted RNA from these clinical samples were run alongside 14 negative controls. The summary of the results is shown in the table below. The samples ranged in Ct value from 15-38 (7-log range).

| | | Clear Dx™ SARS-CoV-2 Test | | |
|----------------------------------|----------|--------------------------------|----------|-------|
| | | Positive | Negative | Total |
| EUA Comparator assay | Positive | 50 | 0 | 50 |
| | Negative | 0 | 32 | 32 |
| Positive Percent Agreement (PPA) | | 50/50 (100%) 95%CI 92.9-100% | | |
| Negative Percent Agreement (NPA) | | 32/32 (100%) 95%CI 89.3 – 100% | | |

Summary of Clinical evaluation results

FDA SARS-CoV-2 Reference Panel Testing

The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded samples and a standard protocol provided by the FDA. The study included a range finding study and a confirmatory study for LoD. Blinded sample testing was used to establish specificity and to confirm the LoD. The extraction of RNA was performed manually using the MagMax Viral RNA Isolation Kit and the extracted RNA was processed directly through the Clear Dx platform as explained in the EUA.

Summary of LoD Confirmation Result using the FDA SARS-CoV-2 Reference Panel








| Reference Materials Provided by FDA | Specimen Type | Product LoD | Cross-Reactivity |
|-------------------------------------|---------------|--------------------------|------------------|
| SARS-CoV-2 | NP swabs | 5.4×10^3 NDU/mL | N/A |
| MERS-CoV | | N/A | ND |

NDU/mL = RNA NAAT detectable units/mL

N/A: Not applicable

ND: Not detected at the highest concentration supplied

Symbols Legend

| Symbol | Meaning |
|--|------------------------------------|
|  | Catalog Number |
|  | In Vitro Diagnostic Medical Device |
|  | Batch Number |
|  | Manufacturer |
|  | Expiration Date YYYY-MM-DD |
|  | Temperature Limitation |
|  | For Prescription Use Only |

Clear Labs
1559 Industrial Road, San Carlos, CA, 94070
Technical Support: 650-257-3304 or email service@clearlabs.com
<https://www.clearlabs.com/>